PT Indofood CBP Sukses Makmur Tbk produces and sells food products in Indonesia, the rest of Asia, Africa, and internationally.
FAIL · Does not pass the screen
6,850.00 IDR
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Indofood CBP Sukses holds its Markdown at $6,850.00. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2025-12-31
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$6,850.00
Valuation
8.73 trailing · 7.56 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.02
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.99%
Below 33%
Interest-bearing debt is 35.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.70%
Below 33%
Cash held in interest-bearing accounts and securities is 1.7% of assets, under the one-third limit.
Pass
Receivables
28.84%
Below 49%
Money owed to the company is 28.8% of assets, under the 49% limit.
Pass
Revenue purity
1.08%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 74% discount to our $11,906.25 fair value, 7.60% revenue growth.
Fair value range in IDR, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. A 73.8% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +39% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 7.6x forward earnings, the price already runs ahead of the business. Our fair value sits at $11,906.25, below where it trades today.
The risks · The things to watch: its business and earnings are exposed to Indonesia and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ICBP.JK trades on IDX (the company is based in Indonesia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059.
2026-07-30Markup$6,850.00+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Markup$6,850.00+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Markup$6,850.00+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Markup$6,850.00+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Markup$6,850.00+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Markup$6,850.00+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Markup$6,850.00+7.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$6,350.00+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (21 analysts) rates it buy, with a mean price target of $10059.
2026-07-03Markup$6,350.00+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$7,100.00
-12.0%
·
$880
-12.0%
2 months
$7,375.00
-15.3%
·
$848
-15.3%
3 months
$7,575.00
-17.5%
·
$825
-17.5%
6 months
$8,075.00
-22.6%
·
$774
-22.6%
1 year
$10,399.41
-39.9%
$250.00
$625
-37.5%
2 years
$10,055.77
-37.9%
$450.00
$666
-33.4%
3 years
$10,714.10
-41.7%
$638.00
$643
-35.7%
5 years
$7,324.51
-14.7%
$1,068.00
$999
-0.1%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever ICBP.JK does next, these words stay.
Indofood CBP Sukses · ICBP.JK · Markdown · $6,850.00
Recorded 2025-12-31 · before the outcome · scored mechanically
